Pancreatic Cancer Research

ResearcherWuhan Union HospitalActive in the last 2 years

Dianyun Ren

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8356-0710; OpenAlex author ID A5064246278. Sources: OpenAlex.

Their work

Papers
22 (first author 5, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
35
Papers, trials and grants by year

2020: 5 papers · 2021: 6 papers · 2022: 6 papers · 2023: 2 papers · 2024: 1 paper · 2025: none · 2026: 2 papers

Papers 22

  1. E2F3 activates NF-κB signaling through TRIM26 mediated TAB1 ubiquitination in pancreatic cancer. Co-author DOI 10.7150/ijbs.127710↗
  2. HDAC1 Regulates Acquired Resistance to EGFR Inhibitors through the TFCP2-NDRG1 Signaling Axis in Pancreatic Cancer. Last author DOI 10.7150/ijbs.131003↗
  3. Ubiquitin ligase TRIM15 promotes the progression of pancreatic cancer via the upregulation of the IGF2BP2-TLR4 axis. Last author DOI 10.1016/j.bbadis.2024.167183↗
  4. MST2 methylation by PRMT5 inhibits Hippo signaling and promotes pancreatic cancer progression. Last author DOI 10.15252/embj.2023114558↗
  5. Correction for: Using ESTIMATE algorithm to establish an 8-mRNA signature prognosis prediction system and identify immunocyte infiltration-related genes in Pan… First author DOI 10.18632/aging.205456↗
  6. USP22-mediated deubiquitination of PTEN inhibits pancreatic cancer progression by inducing p21 expression. Co-author DOI 10.1002/1878-0261.13137↗
  7. ITGA2 induces STING expression in pancreatic cancer by inducing DNMT1 degradation. Last author DOI 10.1007/s13402-022-00731-3↗
  8. ITGA2 overexpression inhibits DNA repair and confers sensitivity to radiotherapies in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215855↗
  9. HDAC5 Loss Enhances Phospholipid-Derived Arachidonic Acid Generation and Confers Sensitivity to cPLA2 Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-21-4362↗
  10. Overexpressed integrin alpha 2 inhibits the activation of the transforming growth factor β pathway in pancreatic cancer via the TFCP2-SMAD2 axis. Last author DOI 10.1186/s13046-022-02286-5↗
  11. HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer. Co-author DOI 10.7150/thno.69444↗
  12. TRIM15 promotes the invasion and metastasis of pancreatic cancer cells by mediating APOA1 ubiquitination and degradation. First author DOI 10.1016/j.bbadis.2021.166213↗
  13. SGLT2 promotes pancreatic cancer progression by activating the Hippo signaling pathway via the hnRNPK-YAP1 axis. Co-author DOI 10.1016/j.canlet.2021.07.035↗
  14. Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer. First author DOI 10.1038/s41419-021-04118-4↗
  15. NR5A2 transcriptional activation by BRD4 promotes pancreatic cancer progression by upregulating GDF15. Co-author DOI 10.1038/s41420-021-00462-8↗
  16. Overexpressed WDR3 induces the activation of Hippo pathway by interacting with GATA4 in pancreatic cancer. Co-author DOI 10.1186/s13046-021-01879-w↗
  17. COL11A1 is the Key Target Gene of MIST1 on Tumor Progression of Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-793040/v1↗
  18. The prognostic value of modified Glasgow Prognostic Score in pancreatic cancer: a meta-analysis. First author DOI 10.1186/s12935-020-01558-4↗
  19. Using ESTIMATE algorithm to establish an 8-mRNA signature prognosis prediction system and identify immunocyte infiltration-related genes in Pancreatic adenocar… First author DOI 10.18632/aging.102931↗
  20. COL11A1 acted as a downstream of Mist1 to promote the EMT in pancreatic cancer Co-author DOI 10.21203/rs.3.rs-108113/v1↗
  21. The aberrant expression of ADAR1 promotes resistance to BET inhibitors in pancreatic cancer by stabilizing c-Myc. Co-author PMID 32064158↗
  22. Metformin activates the STING/IRF3/IFN-β pathway by inhibiting AKT phosphorylation in pancreatic cancer. Co-author PMID 33042621↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Heshui Wu · 18 shared papers, 2020–2026 · strength 2.98
  2. Xin Jin · 14 shared papers, 2020–2023 · strength 2.17
  3. Yingke Zhou · 8 shared papers, 2021–2026 · strength 1.33
  4. Jingyuan Zhao · 7 shared papers, 2020–2024 · strength 1.03
  5. Yan Sun · 6 shared papers, 2020–2024 · strength 0.90
  6. Gengdu Qin · 5 shared papers, 2020–2024 · strength 0.70
  7. Taoyu Chen · 3 shared papers, 2022–2026 · strength 0.66
  8. Feng Guo · 3 shared papers, 2021–2023 · strength 0.54
  9. Hongkun Cai · 2 shared papers, 2022–2026 · strength 0.49
  10. Zibo Meng · 3 shared papers, 2020–2023 · strength 0.46
  11. Penglin Pan · 3 shared papers, 2022 · strength 0.41
  12. Junpeng Meng · 2 shared papers, 2022–2023 · strength 0.38
  13. Hongkun Cai · 2 shared papers, 2022–2024 · strength 0.36
  14. Zhiqiang Liu · 2 shared papers, 2021 · strength 0.31
  15. Feng Guo · 1 shared paper, 2026 · strength 0.30
  16. Qiyue Zhang · 1 shared paper, 2026 · strength 0.30
  17. Shanmiao Gou · 2 shared papers, 2020–2021 · strength 0.28
  18. Jian Shen · 2 shared papers, 2021–2022 · strength 0.27
  19. Haixin Yu · 2 shared papers, 2022 · strength 0.27
  20. Chong Yang · 2 shared papers, 2021 · strength 0.26
  21. Shikai Zhu · 2 shared papers, 2021–2022 · strength 0.26
  22. Yan Ping Sun · 2 shared papers, 2020–2021 · strength 0.25
  23. Kun Zhang · 1 shared paper, 2023 · strength 0.22
  24. Dan Li · 1 shared paper, 2022 · strength 0.20
  25. Yan Sun · 1 shared paper, 2023 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.